Insulin peglispro
As of the edition of 20 October 2026, Insulin peglispro is a protein: stopped in 2016; acts on INSR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2016
- Kind
- Protein
- Registered trials
- 25, 1 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Immune system; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| INSR | Insulin receptor | P06213 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 13 | 13 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 10 | 9 | 0 | 1 |
| All trials | 25 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2010 to now |